![logo](/logos/XFOR.webp)
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
0.65 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | X4 Pharmaceuticals, Inc. |
Symbool | XFOR |
Munteenheid | USD |
Prijs | 0.652 |
Beurswaarde | 109,777,750 |
Dividendpercentage | 0% |
52-weken bereik | 0.531 - 1.6 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Paula Ragan Ph.D. |
Website | https://www.x4pharma.com |
An error occurred while fetching data.
Over X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)